Engimmune Therapeutics
Engimmune Therapeutics is a biopharmaceutical company founded in 2021 that develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumor cancers. Leveraging proprietary AI-guided protein engineering platforms, Engimmune rapidly identifies and engineers multi-specific soluble TCRs with high target affinity, enhanced stability, and superior safety to trigger potent and durable immune responses against solid tumors. The company is advancing a robust pipeline of novel therapeutics, including a lead asset in preclinical development, aimed at addressing underserved oncology and autoimmune indications. Engimmune's business model focuses on developing transformative treatments through its technology platforms, supported by seed and venture capital investments from notable life science investors such as Novo Holdings and Pureos Bioventures. The company is led by experienced biotherapeutics developers and protein engineers and maintains a strong scientific advisory board and leadership team.
Engimmune Therapeutics
Engimmune Therapeutics is a biopharmaceutical company founded in 2021 that develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumor cancers. Leveraging proprietary AI-guided protein engineering platforms, Engimmune rapidly identifies and engineers multi-specific soluble TCRs with high target affinity, enhanced stability, and superior safety to trigger potent and durable immune responses against solid tumors. The company is advancing a robust pipeline of novel therapeutics, including a lead asset in preclinical development, aimed at addressing underserved oncology and autoimmune indications. Engimmune's business model focuses on developing transformative treatments through its technology platforms, supported by seed and venture capital investments from notable life science investors such as Novo Holdings and Pureos Bioventures. The company is led by experienced biotherapeutics developers and protein engineers and maintains a strong scientific advisory board and leadership team.
TL;DR
Founded: 2021 (Basel/Allschwil, Switzerland area)
Focus: Off-the-shelf soluble T-cell receptor (TCR) therapeutics for solid tumors and immune-mediated diseases
Platform: AI-guided protein engineering to create multi-specific and inhibitory soluble TCRs
Lead stage: Preclinical
Seed financing: May 2022 (co-led by Pureos Bioventures and Novo Holdings)
Company Overview
Problem Domain
Solid tumor oncology and immune-mediated diseases
Founded
2021
Industry
Biotechnology
Funding Track Record
Reported pre-seed activity in Feb 2022 involving BaseLaunch
CHF 15.5M
Seed financing closed May 2022
Investor Signal
“Backed by specialized life-science investors (Pureos Bioventures, Novo Holdings) and participation from early-stage investor BaseLaunch”